GlassScriptPhysician profile
Adam B Mckenzie
NPI 1639433428
$13,817.47
in general payments reported to CMS, 2019-2025
66 companies · $2,758 in 2025
The $2,758 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,354 · 2020: $1,286 · 2021: $1,401 · 2022: $1,589 · 2023: $1,416 · 2024: $2,014 · 2025: $2,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,957 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,956.71 |
| Education | $231.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,807.92 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Uk Limited | $1,724.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,708.79 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Grifols USA, LLC | $779.28 | 2019-2025 | Prolastin-C Liquid, Xembify, Gamunex-C |
| Genentech USA, INC. | $754.72 | 2019-2024 | Xolair, Actemra, Ocrevus |
| Medtronic, INC. | $708.85 | 2022-2025 | Illumisite |
| Genzyme Corporation | $682.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $652.86 | 2019-2025 | Ofev, Jascayd |
| Actelion Pharmaceuticals US, INC. | $620.37 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Insmed, INC. | $596.04 | 2020-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $470.42 | 2019-2025 | Dupixent |
| United Therapeutics Corporation | $356.15 | 2022-2025 | Tyvaso, Tyvaso |
| Merck Sharp & Dohme LLC | $312.91 | 2019-2025 | Zerbaxa, Keytruda, Winrevair |
| Amgen INC. | $251.16 | 2019-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $188.18 | 2019-2023 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.